Is baricitinib (baricitinib tablets) an immunosuppressant and its mechanism of action

Baricitinib (also known as baricitinib, English name: Baricitinib) is an oral small molecule targeted drug, which is indeed an immunosuppressive drug. It is mainly used to treat immune-related diseases such as moderate to severe active rheumatoid arthritis (RA), systemic lupus erythematosus (SLE). As a member of the JAK (Janus kinase) inhibitor family, baricitinib specifically inhibits JAK1 and JAK2, thereby interfering with the signaling pathways of multiple inflammatory factors, thereby regulating the immune system and reducing inflammatory responses.

Its core mechanism of action is to block the cytokine signaling pathway. In the human immune system, cytokines such as interleukins and interferons need to exert immune regulatory functions through the JAK-STAT pathway. Baricitinib inhibits the transcription of inflammation-related genes by inhibiting the activity of JAK1/2 and preventing the phosphorylation process of STAT protein. This mechanism of action can effectively reduce the abnormal activation of immune cells and the release of inflammatory mediators, and improve the chronic inflammatory state in autoimmune diseases.

However, due to its immunosuppressive effects, baricitinib should be used with caution. Reduced immune function may increase the risk of infections, including upper respiratory tract infections, herpes zoster, pneumonia, and opportunistic infections such as tuberculosis. In addition, some patients may experience increased blood lipids, abnormal liver function or risk of thrombosis during long-term use. Therefore, blood routine, liver and kidney function, and blood lipid levels should be checked regularly during use, and the medication should be used rationally according to the guidance of a doctor.

In general, baricitinib is an immunosuppressant with a clear mechanism and precise efficacy, and is suitable for the systemic treatment of a variety of autoimmune diseases. It inhibits abnormal immune responses by precisely intervening in the JAK signaling pathway, providing new treatment options for intractable diseases such as rheumatoid arthritis and lupus erythematosus. However, in clinical use, efficacy and risks need to be weighed to ensure standardized treatment under the supervision of professional physicians.

Reference materials:https://www.drugs.com/